{"id":"renogen","rwe":[],"tags":[],"trials":[],"_chembl":null,"aliases":["Epoietin Alpha"],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Renogen","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:30:32.867306+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:30:47.685373+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:30:39.109679+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Renogen","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:30:39.992860+00:00"}},"offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"Renogen, marketed by the National Kidney and Transplant Institute in the Philippines, holds a unique position in the renal therapy market. The drug's key composition patent is set to expire in 2028, providing a period of exclusivity that supports its competitive edge. However, the lack of detailed clinical trial results and revenue data poses a significant risk in assessing its long-term market sustainability.","ecosystem":[],"_scrapedAt":"2026-03-28T00:04:43.880Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:30:47.685912+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT03286712","phase":"PHASE4","title":"The Effect on Vascular Reactivity Using the Erythropoeitin Alpha on Incident Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"National Kidney and Transplant Institute, Philippines","startDate":"2015-10","conditions":"Chronic Kidney Disease, Anemia, Complication of Peritoneal Dialysis","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":3,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Renogen","genericName":"Renogen","companyName":"National Kidney and Transplant Institute, Philippines","companyId":"national-kidney-and-transplant-institute-philippines","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:30:47.685912+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}